BsAbs in RRMM Key Updates
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

Released: February 11, 2025

Expiration: February 10, 2026

Activity

Progress
1
Course Completed

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:

  • Early results with teclistamab combined with anti-CD38 therapy
  • Real-world data with teclistamab including its use after other BCMA-targeted therapies
  • Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
  • Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy